Iron metabolism in end stage renal failure: rationale for re-evaluation of parenteral iron therapy.
OBJECTIVE
In this article we will examine the basis for using chronic high dose parenteral iron therapy in dialysis patients.


RESULTS
There are increasing data that dialysis patients fare better in many respects if they have higher hematocrit values although the real optimal hematocrit has not been defined. There is an increasing tendency to use parenteral iron to achieve this goal.


CONCLUSIONS
Although parenteral iron achieves seemingly favourable short results, there are no data for its safety in the long term. On the contrary, there are reasons to suggest possible iron overload with chronic use.
Moe
Orson W
OW
Department of Internal Medicine, University of Texas Southwestern Medical Center and Medical Service, Dallas 75390, USA. orson.moe@utsouthwestern.edu
Vazquez
Miguel
M
Kielar
Mariusz
M
D018798:Anemia, Iron-Deficiency / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007501:Iron / Q000378:metabolism*; D007505:Iron-Dextran Complex / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D007677:Kidney Function Tests; D008297:Male; D011379:Prognosis; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D007505:Iron-Dextran Complex; D007501:Iron